Graduate School of Frontier Sciences, The University of Tokyo Department of
Integrated Biosciences

Through my graduate school days, I was able to clarify the relationship between IL-7R signal and FYN as a cause of the abnormal cytokinesis in the immune cells. There, I learned the pleasure of the discovery for the first time. Subsequently, we conducted research on producing pancreatic β cells from ES cells for the type 1 diabetes treatment, which resulted in developing a method for monitoring and purifying endoderm stem cells via two specific antibodies. Currently, we are focusing on drug delivery systems (DDS). DDS technology would allow us to provide an ultimate anti-cancer drug with strong anti-tumor effects and without or fewer adverse effects. In addition, we are developing next-generation antibody drugs such as ADC (antibody-drug conjugate), RIT (radioimmunotherapy), and BsAb (bispecific antibody). We are also conducting unique drug discovery research utilizing molecular imaging and mass spectrometry analysis combined with informatics in order to visualize their delivery and the controlled drug release, and molecular cell biology methods to enhance the host immune reaction for the cure of cancer. Furthermore, we will develop a novel cancer diagnosis and treatment which target cancer smell and biomolecules. We welcome graduate students who are interested in our research.